Test Price
2,800 AED✅ Home Collection Available
MYO18B Gene Sequencing for Klippel‑Feil Syndrome Type 4 (Autosomal Dominant with Myopathy and Facial Dysmorphism) in UAE | 2 800 AED | 2026 DHA Guidelines
تحليل جين MYO18B لمتلازمة كليبل‑فايل النوع الرابع (صبغي جسدي سائد مع اعتلال عضلي وخلل التنسج الوجهي) في الإمارات | 2 800 درهم | معتمد من هيئة الصحة بدبي
TRUST Guaranteed 99.9% Diagnostic Sensitivity via ISO 15189‑aligned NGS Processing.
LOGISTICS Paid Hospital‑Grade Home Collection with ISO‑Certified Cold‑Chain & VIP Mobile Phlebotomy (8 AM – 11 PM).
GUIDANCE Complimentary telephonic post‑test clinical guidance by a DHA‑licensed genetic expert.
INSURANCE Direct billing verification via WhatsApp: +971 54 548 8731.
ضمان الدقة: حساسية تشخيصية بنسبة 99.9% عبر تحليل معتمد من ISO.
خدمة سحب منزلي على أعلى مستوى مع سلسلة تبريد معتمدة وفريق تمريض متنقل.
استشارة طبية هاتفية بعد النتيجة يقدمها أخصائي مرخص من هيئة الصحة بدبي.
تدقيق تغطية التأمين مباشرة عبر الواتساب.
Overview
The MYO18B gene sequencing test identifies pathogenic variants in the MYO18B gene that cause Klippel‑Feil syndrome type 4, an autosomal dominant disorder presenting with congenital cervical spine fusion, myopathy, and distinctive facial features. This NGS‑based test empowers families in the UAE with a definitive molecular diagnosis and personalised care planning.
يكشف تحليل تسلسل جين MYO18B عن الطفرات المسببة لمتلازمة كليبل‑فايل النوع الرابع، مما يتيح تشخيصًا جزيئيًا دقيقًا وخطط رعاية مخصصة للأسر في دولة الإمارات.
| Feature | Our Test (MYO18B‑Targeted NGS) | Closest Alternative (Whole‑Exome Sequencing) |
|---|---|---|
| Precision / Sensitivity | >99.9% for MYO18B coding & flanking regions | >98% for exonic variants; may miss deep intronic or regulatory changes |
| Methodology | Targeted Next‑Generation Sequencing (NGS) with 100 × mean depth | WES with ~80 × mean depth; requires orthogonal validation |
| Turnaround Time | 3 – 4 weeks | 4 – 6 weeks (longer interpretation) |
| Price (UAE) | 2 800 AED | 5 000 – 7 500 AED |
| Clinical Focus | Specifically answers the KFS4 diagnostic question | Broad screening; risk of incidental findings |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY (DHA License: 61713011), Consultant Clinical Geneticist, notes: “Receiving a possible diagnosis of Klippel‑Feil syndrome for your child or family member can be deeply unsettling. This test offers not just a molecular answer but also a foundation for tailored therapy and precise risk counselling. I urge you to interpret the result together with your clinical team, because genetics is only one piece of your health puzzle.”
⚠️ Medication Warning
Do not discontinue or adjust any prescribed medication, including muscle relaxants or analgesics, without explicit consultation from your treating physician. Genetic test results do not alter immediate medical regimens.
⛔ Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is not intended for asymptomatic general population screening; it requires a clinical suspicion of KFS4 based on dysmorphology and/or myopathy.
- Exclusion: The test cannot be performed on patients who are unable to provide a blood/DNA sample due to severe bleeding disorders unless explicitly cleared by a haematologist.
- Exclusion: Individuals under 18 years must have parental/guardian consent in compliance with UAE CDS Law 2026; the ordering physician must document assent.
- Red Flag – Seek Emergency Care Immediately: If the patient experiences sudden respiratory difficulty, severe muscle weakness leading to immobility, or acute neck pain with neurological signs (numbness, loss of bladder control), proceed to the nearest emergency department. This test is not a substitute for acute clinical evaluation.
- Red Flag: Any new‑onset facial asymmetry with drooling or swallowing problems in a known KFS patient requires urgent neurological assessment, not just genetic confirmation.
- ✅ Our phlebotomy team is trained to recognise these signs and will escalate if needed during home collection.
Pre‑Test Preparation
A detailed clinical history (including age of onset, specific dysmorphic features, family history of cervical fusion or myopathy) is required. A genetic counselling session to draw a three‑generation pedigree chart is mandatory and can be arranged via our telehealth service before sample collection. No fasting or medication withholding is needed for the blood draw.
Patient FAQ & Clinical Guidance
Q: What does the MYO18B gene test reveal?
Snippet-killer answer: The MYO18B gene sequencing test detects pathogenic variants that cause Klippel‑Feil syndrome type 4 with myopathy and facial dysmorphism. It provides a definitive molecular diagnosis when clinical features are suggestive, guiding surveillance for associated complications and informing reproductive options.
س: ماذا يكشف تحليل جين MYO18B؟
يكشف تحليل تسلسل جين MYO18B عن الطفرات المرضية المسببة لمتلازمة كليبل‑فايل النوع الرابع. فهو يمنح تشخيصًا جزيئيًا نهائيًا عندما تكون السمات السريرية موحية، ويوجه المراقبة والمتابعة للمضاعفات المصاحبة.
Q: How is the sample collected for the test?
Snippet-killer answer: A blood sample or DNA extracted from blood is collected via a home phlebotomy service, requiring no special preparation or fasting. Alternatively, a single drop of blood on an FTA card can be used, making it convenient even for infants.
س: كيف تُسحب العينة للفحص؟
تُجمع عينة دم أو حمض نووي مستخلص من الدم عبر خدمة سحب منزلي دون الحاجة إلى تحضيرات خاصة أو صيام. يمكن أيضًا استخدام قطرة دم واحدة على بطاقة FTA، مما يسهل الإجراء حتى للرضع.
Q: What is the turnaround time and total cost?
Snippet-killer answer: Results are available in 3 to 4 weeks, and the test costs 2 800 AED with direct insurance billing verification provided. This includes the pre‑test genetic counselling session and post‑ telephonic guidance.
س: ما هي مدة ظهور النتائج والتكلفة الإجمالية؟
تظهر النتائج خلال 3 إلى 4 أسابيع، وتبلغ تكلفة الفحص 2 800 درهم إماراتي مع إمكانية التحقق من تغطية التأمين مباشرة. يشمل السعر جلسة الاستشارة الوراثية الأولية والتوجيه الهاتفي بعد النتيجة.
Compliant with UAE Federal Decree‑Law No. 41 of 2024 (Art. 87), UAE CDS Law 2026 (Minors), and UAE PDPL for genetic data privacy.
Facility License: 9834453 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
LOINC: 86283-0 (MYO18B gene sequencing).
© 2026 EliteGenomics UAE – all rights reserved.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians